Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
University of Iowa · NCT06489249
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–24 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 24
- US sites recruiting
- 2
- Study start
- August 15, 2024
- Record last updated
- December 15, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.
Being studied: Placebo; Salsalate 750 MG Oral Tablet [DISALCID]
Conditions: Electronic Cigarette Use; Endothelial Dysfunction; Inflammation
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 18 - 24 years of age
- no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use).
Exclusion Criteria
- tobacco cigarette use (current or history of)
- use of stimulant drugs
- skin diseases
- cardiovascular disease
- diagnosed or suspected hepatic or metabolic disease including diabetes
- statin or other cholesterol-lowering medication
- antihypertensive medication
- current pregnancy or breastfeeding
- blood pressure greater than or equal to 140mmHg systolic and/or greater than or equal to 90mmHg diastolic
- allergy to materials used during the experiment
- known allergies to salsalate or other study drugs
Recruiting US locations
Iowa Bioscience Innovation Facility
Iowa City, IA 52242
Site contact: Anna Stanhewicz, P.h.D · 319-467-1732 · anna-stanhewicz@uiowa.edu
University of Iowa
Iowa City, IA 52242
Site contact: Anna Stanhewicz, PhD · 319-467-1732 · anna-stanhewicz@uiowa.edu
Study contacts (from the official record)
- Anna Stanhewicz, PhD · 3194671732 · anna-stanhewicz@uiowa.edu
Similar studies in Iowa
All smoking & vaping studies in Iowa →- RecruitingHealthy volunteersEarly Phase 1
Sex Differences in the Vascular Effects of E-cigarette Use
Anna Stanhewicz, PhD
- Location
- Iowa City, IA
- Eligibility basics
- Ages 18–24